August Troendle Sells 13,995 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 13,995 shares of Medpace stock in a transaction on Friday, August 21st. The shares were sold at an average price of $624.45, for a total value of $8,739,177.75. Following the transaction, the chief executive officer directly owned 547,200 shares of the company’s stock, valued at approximately $341,699,040. The trade was a 2.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $619.05 on Thursday. The company’s fifty day moving average is $559.49 and its 200-day moving average is $493.31. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The company has a market capitalization of $17.28 billion, a PE ratio of 36.29, a P/E/G ratio of 2.74 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter last year, the company posted $3.10 EPS. The firm’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace remains near a potential technical buy point of $628.92 after its July advance. The stock is trading well above its 50-day and 200-day moving averages, indicating sustained momentum. Medpace Stock Hovers Near Entry, Offers Second Chance After July Spike
• Positive Sentiment: The company’s latest quarterly results exceeded expectations: adjusted earnings were $4.25 per share versus the $3.98 consensus estimate, while revenue rose 17.2% year over year to $707.33 million, surpassing forecasts. Fiscal 2026 EPS guidance remains $17.25 to $17.95.
• Positive Sentiment: Institutional investors and hedge funds own approximately 78% of Medpace, and several investment firms have recently increased their positions. Some analysts have also raised price targets, including RBC’s $692 target and Mizuho’s $665 target.
• Neutral Sentiment: Value-focused investors are comparing Medpace with Concentra Group, but the available report does not establish a clear valuation advantage for MEDP. The stock trades at roughly 36 times earnings, with a PEG ratio above 2.7, suggesting investors are already paying a premium for growth. CON vs. MEDP: Which Stock Should Value Investors Buy Now?
• Neutral Sentiment: Reported short interest was zero shares, producing a zero-day days-to-cover ratio. This provides no meaningful evidence of short-covering demand or downside pressure.
• Negative Sentiment: Several executives have recently sold shares near $620–$625. CEO August Troendle sold 15,978 shares in two transactions worth approximately $9.97 million, while CFO Kevin Brady sold 3,400 shares valued at about $2.13 million. Although both executives retain shares, the concentration of insider selling could weigh on sentiment. Medpace CEO August Troendle Sells 1,983 Shares
• Negative Sentiment: Analyst opinion remains cautious overall: the consensus rating is “Hold,” and the average price target of $584.18 is below recent trading levels. This may make additional upside more difficult without another earnings or guidance catalyst.

Institutional Trading of Medpace

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System boosted its position in Medpace by 53,619.6% in the 2nd quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company’s stock valued at $7,408,778,000 after buying an additional 13,963,607 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of Medpace in the 2nd quarter valued at $1,323,047,000. AQR Capital Management LLC raised its position in shares of Medpace by 31.6% during the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after acquiring an additional 324,293 shares during the last quarter. Wasatch Advisors LP raised its position in shares of Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after acquiring an additional 116,354 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after acquiring an additional 24,625 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on MEDP. Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and raised their price target for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. BMO Capital Markets lifted their price objective on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. Mizuho boosted their price objective on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Finally, Robert W. Baird lifted their price target on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.